Exploring the activity of a polyazine bridged Ru(ii)-Pt(ii) supramolecule in F98 rat malignant glioma cells

Jie Zhu; José Á Rodríguez-Corrales; Reece Prussin; Zongmin Zhao; Anthony Dominijanni; Samantha L Hopkins; Brenda S J Winkel; John L Robertson; Karen J Brewer

doi:10.1039/c6cc07978d

Exploring the activity of a polyazine bridged Ru(ii)-Pt(ii) supramolecule in F98 rat malignant glioma cells

Chem Commun (Camb). 2016 Dec 20;53(1):145-148. doi: 10.1039/c6cc07978d.

Authors

Jie Zhu¹, José Á Rodríguez-Corrales¹, Reece Prussin², Zongmin Zhao³, Anthony Dominijanni², Samantha L Hopkins¹, Brenda S J Winkel⁴, John L Robertson², Karen J Brewer

Affiliations

¹ Department of Chemistry, Virginia Tech., Blacksburg, Virginia 24061-0212, USA.
² School of Biomedical Engineering and Sciences, Virginia Tech., Blacksburg, Virginia 24061-0212, USA.
³ Department of Biological Systems Engineering, Virginia Tech., Blacksburg, Virginia 24061-0212, USA.
⁴ Department of Biological Sciences, Virginia Tech., Blacksburg, Virginia 24061-0406, USA. winkel@vt.edu.

PMID: 27901157
DOI: 10.1039/c6cc07978d

Abstract

The mixed-metal supramolecular complex, [(Ph₂phen)₂Ru(dpp)PtCl₂]²⁺, displays significant DNA modification, cell growth inhibition, and toxicity towards F98 malignant glioma cells following visible light irradiation. The design of this complex affords superior cellular uptake and antiproliferative activity compared to the classic chemotherapeutic agent, cisplatin.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / chemistry*
Antineoplastic Agents / pharmacology*
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Proliferation / radiation effects
Glioma / pathology*
Light
Models, Molecular
Molecular Conformation
Organometallic Compounds / chemistry*
Organometallic Compounds / pharmacology*
Platinum / chemistry*
Rats
Ruthenium / chemistry*

Substances

Antineoplastic Agents
Organometallic Compounds
Platinum
Ruthenium